Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842175 | 0.92 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL6207560 | 0.91 | CNR1 (0.39) | CNR1CNR2 | |
| SCHEMBL4842366 | 0.86 | CNR1 (0.45) | CNR1CNR2 | |
| SCHEMBL4841187 | 0.86 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL4836443 | 0.82 | CNR1 (0.43) | CNR1CNR2 | |
| SCHEMBL5383708 | 0.81 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL1315433 | 0.80 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL5381183 | 0.79 | CNR1 (0.55) | CNR1CNR2 | |
| SCHEMBL5390432 | 0.76 | CNR1 (0.64) | CNR1CNR2 | |
| SCHEMBL5390202 | 0.76 | CNR1 (0.53) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7329658-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC (US) | 2008-02-12 | — | — | US | disclosed |
| CN-1768061-A | Pyrazolo[1,5-a][1,3,5]triazine derivatives as cannabinoid receptor ligands | PFIZER PROD INC (US) | 2006-05-03 | — | — | CN | disclosed |
| EP-1592691-A1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004069837-A1 | PYRAZOLO`1,5-A!`1,3,5!TRIAZINE DERIVATIVES AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157839-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.